In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

The low response rate of immune checkpoint blockade in breast cancer has highlighted the need for predictive biomarkers to identify responders. While a number of clinical trials are ongoing, testing all possible combinations is not feasible. In this study, a quantitative systems pharmacology model i...

Full description

Bibliographic Details
Main Authors:	Hanwen Wang, Oleg Milberg, Imke H. Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin Roskos, Cesar A. Santa-Maria, Aleksander S. Popel
Format:	Article
Language:	English
Published:	The Royal Society 2019-05-01
Series:	Royal Society Open Science
Subjects:	immuno-oncology immune checkpoint inhibitor computational model systems biology computational biology
Online Access:	https://royalsocietypublishing.org/doi/pdf/10.1098/rsos.190366

Similar Items

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
by: Hanwen Wang, et al.
Published: (2020-02-01)

Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors
by: Chang Gong, et al.
Published: (2019-01-01)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
by: Tristan Rupp, et al.
Published: (2022-06-01)

Mathematical modelling and transcriptional characterisation of intratumoral regulatory T cell sub-populations
by: Muzhingi, I
Published: (2023)

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response
by: Shuming Zhang, et al.
Published: (2021-10-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
by: Connor Frey, et al.
Published: (2024-07-01)

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
by: Chuah, Samuel, et al.
Published: (2022)

Editorial: Systems Biology Methods in Computational Immuno-Oncology
by: Andrei S. Rodin, et al.
Published: (2022-04-01)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
by: Judith A. Seidel, et al.
Published: (2018-03-01)

ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data
by: James W Opzoomer, et al.
Published: (2021-04-01)

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
by: Xin Su, et al.
Published: (2024-08-01)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
by: Joseph Mabbitt, et al.
Published: (2023-08-01)

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
by: Won Jin Ho, et al.
Published: (2022-11-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Patient-Specific Cell Communication Networks Associate With Disease Progression in Cancer
by: David L. Gibbs, et al.
Published: (2021-08-01)

Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager
by: Samira Anbari, et al.
Published: (2023-06-01)

Protocol for simulating macrophage signal transduction and phenotype polarization using a large-scale mechanistic computational model
by: Chen Zhao, et al.
Published: (2021-09-01)

Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model
by: Field, Cameron S., et al.
Published: (2019)

In silico molecular understanding of opioid receptor activation
by: Velgy, N
Published: (2018)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
by: Haoyang Mi, et al.
Published: (2022-05-01)

An inhibitory role for human CD96 endodomain in T Cell anti-tumor responses
by: Wang, Chelsia Qiuxia, et al.
Published: (2023)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
by: Yun Hu, et al.
Published: (2022-11-01)

Exploring the potential of aqueous extracts of Artemisia annua ANAMED (A3) for developing new anti‐malarial agents: In vivo and silico computational approach
by: Victor Onukwube Apeh, et al.
Published: (2024-09-01)

Immuno-Imaging (PET/SPECT)–Quo Vadis?
by: Carsten S. Kramer, et al.
Published: (2022-05-01)

Employing computational tools to design a multi-epitope vaccine targeting human immunodeficiency virus-1 (HIV-1)
by: Hamza Sher, et al.
Published: (2023-05-01)

Anti-angiogenic collagen IV-derived peptide target engagement with αvβ3 and α5β1 in ocular neovascularization models
by: Raquel Lima e Silva, et al.
Published: (2023-02-01)

In Vitro and In Silico Anti-Arboviral Activities of Dihalogenated Phenolic Derivates of L-Tyrosine
by: Vanessa Loaiza-Cano, et al.
Published: (2021-06-01)

Annotating new genes : from in silico screening to experimental validation /
by: Uchida, Shizuka
Published: (2012)

Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma
by: Juan Wu, et al.
Published: (2022-12-01)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
by: Ze Xiang, et al.
Published: (2022-05-01)

Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy
by: Matteo Pallocca, et al.
Published: (2019-04-01)

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
by: Stephanie Dorta-Estremera, et al.
Published: (2019-09-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
by: Thomas Morgan Hulen, et al.
Published: (2023-06-01)

Computational biology /
by: Fenyo, David
Published: (c201)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications
by: Clyde John, et al.
Published: (2022-12-01)

Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application
by: Shijia ZHANG, et al.
Published: (2017-09-01)

Aqueous extract from Madhuca indica bark protects cells from oxidative stress caused by electron beam radiation: in vitro, in vivo and in silico approach
by: K. Vinutha, et al.
Published: (2019-05-01)